Translation of In Vitro Metabolic Data to Predict In Vivo Drug–Drug Interactions: IVIVE and Modeling and Simulations

作者: Amin Rostami-Hodjegan

DOI: 10.1007/978-1-4419-0840-7_13

关键词:

摘要: For many years, researchers have been able to study xenobiotic metabolism using several in vitro systems. However, quantitative translation of the information, which requires appropriate understanding link between these systems and human body, is still its infancy. Recent progress biology, advent powerful computers capable handling numerous complicated non-linear models realization that there virtually no end number various studies would be required cover all possible permutations clinical scenarios can occur real life contributed increased prominence vitro–in vivo extrapolation (IVIVE) virtual modeling simulation drug discovery development. This chapter provides an overview translational aspects describes prerequisite data, tools applied for prediction metabolic drug–drug interactions (M-DDI).

参考文章(64)
K. S. Pang, M. Chiba, Metabolism: Scaling-up from In Vitro to Organ and Whole Body Pharmacokinetics of Drugs. ,vol. 110, pp. 101- 187 ,(1994) , 10.1007/978-3-642-78680-8_5
Mats O. Magnusson, Pharmacodynamics of enzyme induction and its consequences for substrate elimination. Acta Universitatis Upsaliensis. ,(2007)
Amin Rostami‐Hodjegan, Peter R. Jackson, Geoffrey T. Tucker, Sensitivity of Indirect Metrics for Assessing “Rate” in Bioequivalence Studies—Moving the “Goalposts” or Changing the “Game” Journal of Pharmaceutical Sciences. ,vol. 83, pp. 1554- 1557 ,(1994) , 10.1002/JPS.2600831107
Ying-Hong Wang, David R. Jones, Stephen D. Hall, PREDICTION OF CYTOCHROME P450 3A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITES Drug Metabolism and Disposition. ,vol. 32, pp. 259- 266 ,(2004) , 10.1124/DMD.32.2.259
R L Lalonde, K G Kowalski, M M Hutmacher, W Ewy, D J Nichols, P A Milligan, B W Corrigan, P A Lockwood, S A Marshall, L J Benincosa, T G Tensfeldt, K Parivar, M Amantea, P Glue, H Koide, R Miller, Model-based drug development. Clinical Pharmacology & Therapeutics. ,vol. 82, pp. 21- 32 ,(2007) , 10.1038/SJ.CLPT.6100235